Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia

NCT06972264 is registered in ClinicalTrials.gov with Veradermics, Inc. as lead sponsor.

NCT NCT06972264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06972264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia
Lead sponsor
Veradermics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 11, 2025
Completion date
July 31, 2027
Enrollment
480 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

aga, androgenetic alopecia, male pattern baldness